数据
资源
版本对比
免费注册
预约演示
免费注册
Vericel
to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
2024-02-27
·
BioSpace
引进/卖出
细胞疗法
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) --
Vericel Corporation
(NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe
burn
care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Tuesday, March 5, 2024. A webcast of the presentation will be available on the Investor Relations section of the
Vericel Corporation
website at: . About
Vericel Corporation
Vericel
is a leading provider of advanced therapies for the sports medicine and severe
burn
care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives.
Vericel
markets three products in the United States.
MACI
® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness
cartilage defects
of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.
Vericel
also holds an exclusive license for North American rights to
NexoBrid
® (
anacaulase-bcdb
), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit . Epicel and MACI are registered trademarks of
Vericel Corporation
. NexoBrid is a registered trademark of
MediWound Ltd.
and is used under license to
Vericel Corporation
. © 2024
Vericel Corporation
. All rights reserved. Investor Contacts: Eric Burns ir@vcel.com +1 (734) 418-4411 Media Contact: Julie Downs media@vcel.com
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Vericel Corp.
MediWound Ltd.
适应症
烧伤
软骨病变
靶点
-
药物
Autologous cultured chondrocytes (Vericel)
Anacaulase-bcdb
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务